New Systemic Therapies for Advanced Hepatocellular Carcinoma
Since the approval of sorafenib for patients with advanced hepatocellular carcinoma (HCC) in 2007, many drugs have failed in the first and second-line setting. Fortunately, during the recent 2 years, between 2017 and 2018, four drugs (regorafenib, lenvatinib, cabozantinib, and ramucirumab) were foun...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Jin Publishing & Printing Co.
2019-01-01
|
| Series: | The Korean Journal of Gastroenterology |
| Subjects: | |
| Online Access: | http://www.kjg.or.kr/journal/view.html?doi=10.4166/kjg.2019.73.1.10 |